We evaluated vascular density in the ischemic region in all animals seven days after cell transplantation, said study lead author Ren-Ke Li, MD, PhD. The animals exhibited significant reductions in scar size and cell death and improvements in neurological function when compared to controls that received no BMSCs.
Researchers concluded that the intravenous delivery of bone marrow-derived cells may enhance tissue repair and, in turn, functional recovery after a stroke. While the potential mechanisms for this recovery are unclear, among the possibilities are that the brain microenvironment early on following a stroke may mimic brain development. Subsequent elevated levels of growth factors might enhance homing of BMSCs to the injured area and induce cell proliferation.
Our results support the potential therapeutic use of BMSCs after a stroke, concluded Li.
Both studies lend important support to a growing body of laboratory evidence that bone marrow is a remarkable adult stem cell source for transplant therapy following stroke, says Cell Transplantation associate editor Cesar V. Borlongan, Ph.D. of the Medical College of Georgia. The non-invasive MRI visualization of pre-labeled BMSCs could become a routine clinical marker for transplanted cells as well as for safety and efficacy.
|Contact: Jihwan Song|
Cell Transplantation Center of Excellence for Aging and Brain Repair